

<p>TAKEDA PHARMACEUTICAL COMPANY LIMITED, TAKEDA PHARMACEUTICALS NORTH AMERICA, INC., TAKEDA PHARMACEUTICALS LLC, TAKEDA PHARMACEUTICALS AMERICA, INC., and ETHYPHARM, S.A.,</p> <p>Plaintiffs and Counterclaim-Defendants,</p> <p>v.</p> <p>MYLAN PHARMACEUTICALS INC.,</p> <p>Defendant and Counterclaim-Plaintiff.</p>	<p>Civil Action No. 3:11-CV-02506-JAP-TJB</p> <p><b>DECLARATION OF ARLENE L. CHOW IN SUPPORT OF PLAINTIFFS' RESPONSIVE CLAIM CONSTRUCTION BRIEF</b></p>
---	---

I, Arlene L. Chow, declare as follows:

1. I am a partner with the law firm of Hogan Lovells US LLP, counsel for Plaintiffs Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, Takeda Pharmaceuticals America, Inc. and Ethypharm, S.A. (together, "Plaintiffs") in the above-captioned case.

2. I submit this declaration in support of Plaintiffs' Responsive Claim Construction Brief.

3. Attached hereto as Exhibit 30 is a true and correct copy of the Product Label for Fentora®.

4. Attached hereto as Exhibit 31 is a true and correct copy of portions of the deposition transcript of Defendant Mylan Pharmaceuticals Inc's expert, Dr. Russell J. Mumper.

5. Attached hereto as Exhibit 32 is a true and correct copy of portions of the deposition transcript of Plaintiffs' expert, Dr. Stephen R. Byrn.

6. Attached hereto as Exhibit 33 is a true and correct copy of the Office Action dated November 5, 1999 from the Reexamination history of United States Patent No. 5,464,632.

I declare under penalty of perjury that the following is true and correct.

Dated: June 22, 2012

  
Arlene L. Chow